<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04999722</url>
  </required_header>
  <id_info>
    <org_study_id>2021CQSDWRMYYEC-004</org_study_id>
    <nct_id>NCT04999722</nct_id>
  </id_info>
  <brief_title>Establishment and Preliminary Evaluation of Digital Three Level Linkage Whole Process Diabetes Management System</brief_title>
  <official_title>Establishment and Preliminary Evaluation of Digital Three Level Linkage Whole Process Diabetes Management System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chongqing Renji Hospital, University of Chinese Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chongqing Renji Hospital, University of Chinese Academy of Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study used Nan'an District of Chongqing, China as a pilot project to improve the&#xD;
      comprehensive compliance rate of diabetic patients in China, and reduce the physical and&#xD;
      economic harm caused by complications.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 25, 2021</start_date>
  <completion_date type="Anticipated">June 24, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Mobile app was used for follow-up</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline Glycated hemoglobin at 12 months</measure>
    <time_frame>Month 12</time_frame>
    <description>Changes of glycated hemoglobin （percentage）before and after management</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Blood pressure at 12 months</measure>
    <time_frame>Month 12</time_frame>
    <description>Changes of blood pressure（mmHg） before and after management</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline blood lipid at 12 months</measure>
    <time_frame>Month 12</time_frame>
    <description>Changes of blood lipid （mmol/L）before and after management</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Diabetic nephropathy at 12 months</measure>
    <time_frame>Month 12</time_frame>
    <description>Changes of Diabetic nephropathy（ratio） before and after management</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>APP group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with diabetes who had access to a mobile APP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Diabetes participants who accepted the traditional management model</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Traditional mode of management</intervention_name>
    <description>Traditional model management of Diabetes Mellitus patients</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Mobile APP management</intervention_name>
    <description>Management of diabetic patients with mobile phone APP</description>
    <arm_group_label>APP group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinical diagnosis of type 2 diabetes.&#xD;
&#xD;
          2. Aged 18-70;&#xD;
&#xD;
          3. HbA1c ≥ 8.0%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy;&#xD;
&#xD;
          2. Chronic kidney disease (CKD stage 5);&#xD;
&#xD;
          3. Senile dementia patients;&#xD;
&#xD;
          4. With malignant tumor;&#xD;
&#xD;
          5. Moderate and severe anemia;&#xD;
&#xD;
          6. Severe liver dysfunction;&#xD;
&#xD;
          7. Hemolytic anemia, aplastic anemia, massive blood loss or transfusion, chronic malaria;&#xD;
&#xD;
          8. In the recent one week, large doses of salicylate, erythropoietin, antiretroviral&#xD;
             drugs, ribavirin and other drugs that have an impact on the detection of glycosylated&#xD;
             hemoglobin were used&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 19, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Manage</keyword>
  <keyword>Mobile app</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

